Lessons learned from cancer may help in the treatment of pulmonary hypertension.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 15931382.
- Also identified by PMC identifier 1137011.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Hyperplasia of pulmonary artery SMCs (PASMCs) is a pathological hallmark of pulmonary arterial hypertension (PAH). In this issue of the JCI, McMurtry et al. report that adenovirus-mediated overexpression of survivin--a multipotent inhibitor of apoptosis--induces PAH in rats, whereas inhalation of an adenovirus vector encoding a mutant survivin gene with dominant-negative properties reverses established monocrotaline-induced PAH. These findings raise important issues regarding the role of survivin in the pathogenesis of PAH, its value as a prognostic indicator, and its use as a target for new therapeutic strategies.
Medical subject headings
- Apoptosis
- Genetic Therapy
- Hypertension, Pulmonary
- Microtubule-Associated Proteins
- Mutation
- Neoplasms